FDA approves Teva’s expanded indication for Uzedy for bipolar I disorder
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
New study presents a human-relevant stress model for assessing potential therapeutics
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
Physician-led Pi Health has demonstrated capabilities to dramatically reduce clinical trial timelines and administrative burden, while increasing data quality
Ultra-high purity surfactant for biologics and parenteral drug formulations
Merck and Siemens signed new MoU extending their strategic partnership to accelerate digital transformation in the life science industry
Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Subscribe To Our Newsletter & Stay Updated